Most patients with type 1 diabetes will experience clinically meaningful differences in glucose level results when comparing laboratory-measured HbA1c levels with HbA1c levels derived from a glucose management indicator.
The use higher insulin doses in patients with type 1 diabetes can alter several cardiovascular risk factors without increasing cardiovascular outcomes.
Higher levels of vitamin D-binding protein at the time of delivery, but not during the middle of pregnancy, were associated with a lower risk for type 1 diabetes.
An improved genetic risk score for type 1 diabetes significantly improved identification of persons with type 1 diabetes from those with type 2 diabetes and was useful in identifying adult incident diabetes in newborn screening.
Poor glycemic control in patients with newly diagnosed type 1 diabetes, but not type 2 diabetes, was associated with an increased risk for low-trauma fracture.
Only one in five children and adults with type 1 diabetes (T1D) in the United States achieve American Diabetes Association (ADA) goals for glycated hemoglobin.
In young children with type 1 diabetes, even a single episode of moderate/severe diabetic ketoacidosis can have long-term effects on the developing brain.
In patients with long-standing T1D and proliferative diabetic retinopathy, renin-angiotensin-aldosterone system activation may be associated with vascular stiffening.
Professional and personal continuous glucose monitoring systems exhibit similar accuracy in both inpatient and home settings, with both having lower sensor performance during hypoglycemic episodes.
The ADA published its 2019 Standards of Medical Care in Diabetes, an evidence-based document intended to provide clinicians, patients, and other stakeholders in the diabetes treatment landscape with up-to-date recommendations.
Treatment of thyroid disease, severe infections, glucagon prescriptions, and diabetic retinopathy occur more frequently in individuals with type 1 diabetes who are subsequently diagnosed with Addison disease.
